The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy
Viruses · 2026
DOI: 10.3390/v18010142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2026. Verfasst von Tommaso Matucci und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56122 Pisa,…. Hauptthemen laut MEDLINE: Lamivudine, HIV Infections, Hepatitis B, Anti-HIV Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lamivudine/dolutegravir (3TC/DTG) is an effective and well-tolerated antiretroviral regimen for most people with HIV (PWH) who are virologically suppressed; however, specific clinical characteristics, such as prior hepatitis B virus (HBV) exposure or archived resistance-associated mutations (RAMs), may influence the risk of virological failure (VF). We conducted a retrospective, monocentric cohort study to evaluate the incidence and predictors of VF among PWH who switched to 3TC/DTG after achieving virological suppression (HIV-RNA < 50 copies/mL). A total of 188 PWH were included. Over 5082 patient-years of follow-up (PYFU), 8 individuals (4.3%) experienced VF, corresponding to an incidence rate of 1.45 per 1000 PYFU. The cumulative probabilities of VF at 1, 2, 3, 4, and 5 years were 0.6%, 2.7%, 2.7%, 4.2%, and 22.3%, respectively. In exploratory multivariable analyses, anti-HBc positivity was associated with an increased risk of VF (adjusted hazard ratio [aHR] 4.80, 95% CI 1.03–22.43; p = 0.046). After adjustment for age and sex, individuals with anti-HBc positivity who had switched from a tenofovir-containing regimen showed the highest risk of VF compared with anti-HBc-negative individuals without prior tenofovir exposure (aHR 15.06, 95% CI 1.40–161.38; p = 0.025). Given the limited number of virological events, these findings should be interpreted with caution. Nevertheless, they suggest that prior HBV exposure, particularly in the context of tenofovir discontinuation, may represent a clinically relevant factor when considering simplification to 3TC/DTG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56122 Pisa, Italy.
- Virology Unit, Azienda Ospedaliera Universitaria Pisana, University of Pisa, 56122 Pisa, Italy.
ORCID-Profile: Tommaso Matucci, Sara Occhineri, Laura Del Bono, Alberto Borghetti
Zitieren
APA
Matucci, T., Occhineri, S., Palomba, A., Vatteroni, M. L., Del Bono, L., Polidori, M., Iapoce, R., Borghetti, A., & Falcone, M. (2026). The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy. Viruses. https://doi.org/10.3390/v18010142
Vancouver
Matucci T, Occhineri S, Palomba A, Vatteroni ML, Del Bono L, Polidori M, et al. The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy. Viruses. 2026. doi:10.3390/v18010142
BibTeX
@article{Matucci2026,
author = {Matucci, Tommaso and Occhineri, Sara and Palomba, Alessandra and Vatteroni, Maria Linda and Del Bono, Laura and Polidori, Marina and Iapoce, Riccardo and Borghetti, Alberto and Falcone, Marco},
title = {The Role of Prior HBV Infection on the Efficacy of 3TC/DTG as a Maintenance Therapy},
journal = {Viruses},
year = {2026},
doi = {10.3390/v18010142}
}
EUVIMED